Pharmaceutical company Teva has offered to buy fellow drug maker Mylan in a deal that could be worth $40 billion.
In the proposal, confirmed yesterday (April 21), Teva offered Mylan $82 per share.
Last week, Mylan’s executive chairman Robert Coury dismissed rumours of a merger with Israel-based Teva.